NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $78.54 +0.19 (+0.24%) (As of 09/20/2024 08:54 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Dr. Reddy's Laboratories Stock (NYSE:RDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$77.96▼$78.6050-Day Range$78.12▼$84.2152-Week Range$63.72▼$84.46Volume206,300 shsAverage Volume218,833 shsMarket Capitalization$13.11 billionP/E Ratio19.49Dividend Yield0.51%Price Target$87.00Consensus RatingHold Company OverviewDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More… [SHOCKING] Crypto Document Leak… (Ad)A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.Click here to review my research and unique strategy to score potential profits from this under-the- Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 53rd PercentileDr. Reddy's Laboratories scored higher than 53% of companies evaluated by MarketBeat, and ranked 532nd out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth0.49% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 0.49% in the coming year, from $4.11 to $4.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 19.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 19.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.73.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.23% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 9.25%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.51%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 9.93%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.69% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.23% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 9.25%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.83 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dr. Reddy's Laboratories this week, compared to 3 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. RDY Stock News HeadlinesIndian equity markets suffer losses amid increased selling pressureSeptember 20 at 3:28 AM | msn.comDr. Reddy's Laboratories Limited (NYSE:RDY) Forecasted to Earn FY2027 Earnings of $3.12 Per ShareSeptember 14, 2024 | americanbankingnews.comThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.September 23, 2024 | Investors Alley (Ad)Dr. Reddy's Laboratories Limited (RDY)September 11, 2024 | finance.yahoo.comDr. Reddy's Laboratories underperforms Tuesday when compared to competitorsSeptember 3, 2024 | marketwatch.comDr. Reddy's Laboratories underperforms Thursday when compared to competitorsAugust 29, 2024 | marketwatch.comDr. Reddy's Q1FY25 Financial ResultsJuly 27, 2024 | businesswire.comDr Reddys Laboratories earnings: here's what Wall Street expectsJuly 26, 2024 | markets.businessinsider.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $69.58 on January 1st, 2024. Since then, RDY stock has increased by 12.9% and is now trading at $78.54. View the best growth stocks for 2024 here. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings data on Saturday, July, 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by $0.10. The company earned $919.80 million during the quarter, compared to analysts' expectations of $861.68 million. Dr. Reddy's Laboratories had a net margin of 19.28% and a trailing twelve-month return on equity of 20.32%. Who are Dr. Reddy's Laboratories' major shareholders? Top institutional investors of Dr. Reddy's Laboratories include Renaissance Technologies LLC (1.20%), Dimensional Fund Advisors LP (0.60%), Healthcare of Ontario Pension Plan Trust Fund (0.22%) and Millennium Management LLC (0.20%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA) and GSK (GSK). Company Calendar Last Earnings7/27/2024Ex-Dividend for 7/30 Dividend7/30/2024Dividend Payable7/30/2024Today9/23/2024Next Earnings (Estimated)10/25/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,048Year Founded1984Price Target and Rating Average Stock Price Target$87.00 High Stock Price Target$87.00 Low Stock Price Target$87.00 Potential Upside/Downside+10.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$4.03 Trailing P/E Ratio19.49 Forward P/E Ratio19.11 P/E Growth1.74Net Income$668 million Net Margins19.28% Pretax Margin24.88% Return on Equity20.32% Return on Assets14.62% Debt Debt-to-Equity Ratio0.02 Current Ratio2.55 Quick Ratio1.90 Sales & Book Value Annual Sales$288.51 billion Price / Sales0.05 Cash Flow$5.02 per share Price / Cash Flow15.63 Book Value$20.17 per share Price / Book3.89Miscellaneous Outstanding Shares166,893,000Free Float163,555,000Market Cap$13.11 billion OptionableOptionable Beta0.55 Social Links This page (NYSE:RDY) was last updated on 9/23/2024 by MarketBeat.com Staff From Our PartnersThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Dr. Reddy's Laboratories Limited You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.